Session Abstract – PMWC 2022 Silicon Valley


  • Hope or Hype? The Role of ML in Drug Discovery and Development (PANEL)
    Session Chair: Ansuman Satpathy, Stanford University
    - Marcel Hop, Genentech
    - Noam Solomon, ImmunAI
    - Stacie Calad-Thomson, BioSymetrics
    - Andrea deSouza, Eli Lilly and Company
  • Advancing Research and Drug Discovery with UK Biobank
    Session Chair: Asha Collins, DNAnexus
    - Mahesh Pancholi, UK Biobank
  • Machine Learning for Novel Target Discovery: Unique Techniques Meet Unique Data
    Session Chair: Alex Morgan, Khosla Ventures
    - Lindsay Edwards, Relation Therapeutics
    - Kristen Fortney, BioAge
    - Quin Wills, Ochre Bio
    - Joseph Rodgers, Fountain Therapeutics
    - Calum MacRae, Atman Health
  • AI in Small Molecule Design and Screening (PANEL)
    Session Chair: Alex Zhavoronkov, Insilico Medicine
    - Jim Edwards, Janssen
    - Tommaso Mansi, Johnson & Johnson
    - Martin Emanuel Bittner, Arctoris
  • AI/ML in Clinical Trial Design, Patient Selection and Prediction of Outcomes (PANEL)
    Session Chair: Peter Lipsky, Ampel Bio
    - Nasim Eftekhari, City of Hope
    - Mika Newton, xCures, Inc.
    - Mark Smith, MedStar Health
    - William Oh, Sema4
  • Treating Genetics as Data: Computable, Structured Results for Precision Medicine
    - Peter DeVault, Epic
  • PMWC 2022 Showcase
    - Kevin Cho, Envisagenics, Inc.
    - Poojitha Ojamies, Novartis
    - Steve Harrison, Engine Biosciences

 Session Chair Profile

M.D., Ph.D., Assistant Professor, Stanford University

Biography
Dr. Ansuman Satpathy M.D., Ph.D. in the Department of Pathology at Stanford University School of Medicine. He is a member of the Stanford Cancer Institute, the Parker Institute for Cancer Immunotherapy, the Immunology, Cancer Biology, and Biomedical Informatics Programs, Bio-X, and a faculty fellow in ChEM-H. Dr. Satpathy completed an M.D. and Ph.D. in immunology at Washington University in St. Louis, clinical residency in pathology at Stanford Hospital and Clinics, and postdoctoral training in genetics at Stanford University. Dr. Satpathy’s research group focuses on developing and applying genome-scale technologies to study fundamental properties of the immune system in health, infection, and cancer.


 Session Chair Profile

M.D., CEO, CMO, AMPEL BioSolutions

Biography
Peter is a Rheumatologist & Immunologist who immerses himself in basic & clinical research. He received his medical degree from the New York University School of Medicine, completed residency training at the Strong Memorial Hospital in Rochester, New York and his post-doctoral fellowship in NIAID at the NIH. After going to UT Southwestern Medical Center at Dallas, Peter rapidly advanced to become a professor of Internal Medicine and Microbiology as well as the Director of the Harold C Simmons Arthritis Research Center and, Co-Director of the Immunology Graduate Program. He entered the new millennium as the Director of the Intramural Research Program & the Autoimmunity Branch of NIAMS at the NIH. Peter is the co-founder and CEO of AMPEL BioSolutions LLC, a biotech company involved in employing analysis of BigData and Machine Learning to provide personalized medicine. Peter is the former editor of the Journal of Immunology, Nature Reviews Rheumatology and Arthritis Research & Therapy, and is the recipient of the Carol Nachman Prize, the American College of Rheumatology Distinguished Investigator Award and the Arthritis Foundation’s Lee Howley prize.


 Session Chair Profile

Ph.D., CEO, Immunai

Biography
Noam is the CEO and Co-Founder at immunai, the first and only company to map the entire immune system for better detection, diagnosis, and treatment of disease. Leveraging single-cell technologies and machine learning algorithms, immunai has mapped out thousands of immune cells and their functions, building the largest proprietary data set in the world for clinical immunological data. Prior to co-founding immunai, Noam had a dual career in both the industry and academia. Noam is a double PhD, and served as a post-doctoral researcher in the Mathematics department at MIT, and in the center of mathematical sciences and applications at Harvard University. In his research, he developed and applied tools from algebra and Algebraic Geometry in the study of classical problems in combinatorics. Noam also worked as an algorithms developer in the Israeli defense forces and subsequently as a data scientist, consultant and head of data science in several hi-tech companies in Israel.


 Session Chair Profile

Ph.D., General Manager, Biobank Analytic Platforms, DNAnexus

Biography
Dr. Collins has spent the past 20 years as a biologist, strategist, and operational leader focused on transforming and scaling biopharma and healthcare companies. Previously, she was the Head of U.S. Clinical Operations at Genentech, where she was responsible for executing in-sourced, late-stage, pivotal clinical trials for the entire Genentech / Roche product portfolio. Prior to that, Dr. Collins was Vice President and General Manager for the U.S. Clinical Trial Sourcing business at McKesson Corporation and worked as a senior executive focused on life sciences strategy and operations for Fortune 500 companies at Deloitte and Quintiles Consulting. Dr. Collins is also an Aspen Institute Health Innovator Fellow, an independent Corporate Director for IDEXX Laboratories, a member of the Scientific Advisory Board for the Translational Research Institute for Space Health, and a mentor for Backstage Capital. She also worked on The Cancer Genome Atlas project (TCGA), where she focused on managing stakeholder and public communications, as well as the integration of business requirements for the first public database. Dr. Collins earned her PhD in Cancer Biology from the University of Wisconsin-Madison and a Bachelor of Science in Biology from the University of Pittsburgh.

Talk
Cloud-based Research Analytics of Large Population Cohorts
There are multiple large, population cohorts coming online and being planned. We will discuss how cloud-based analytic platforms are allowing innovation and discovery for the maximum number of researchers and as a result the greatest impact on advancing science and healthcare.


 Session Chair Profile

M.D., Ph.D., Partner, Khosla Ventures

Biography
Alex's focus at Khosla Ventures is in biotechnology, healthcare, data science, and AI/ML. Alex has an MD and PhD in biomedical informatics from Stanford, with a dissertation on machine learning methods in precision medicine under the supervision of Atul Butte. Alex has completed additional graduate work in biology and physics and a short postdoctoral fellowship in biochemistry and genetics with Ronald W. Davis at the Stanford Genome Technology Center. As a scientist, he has published over 50 scientific publications, primarily at the intersection of computer science, biology, and healthcare. As an inventor, he has licensed IP to three separate companies. As an entrepreneur, he has worked as an early employee or co-founder at a range of startups. He currently sits on the boards of some of Khosla Ventures’ investments, including Deep Genomics and HeartVista. Alex is committed to improving access to healthcare to underserved communities through community service, and served as co-manager of the volunteer-staffed Arbor Free Clinic in Menlo Park, where he also worked as head of IT and helped develop and deploy their electronic medical records system. Alex is particularly interested in helping to advance diversity in STEM fields, including technology entrepreneurship.


 Speaker Profile

Ph.D., Vice President, Genentech Inc.

Biography
Cornelis E.C.A. “Marcel” Hop is Vice-President at Genentech and supervising the DMPK department. He leads a team of about 85 scientists involved in acquisition and interpretation of ADME data in support of drug discovery and development ranging from early stage research to NDA and beyond. Before that, he was a Senior Director at Pfizer and a Senior Research Fellow at Merck and he received his Ph.D. from the University of Utrecht (The Netherlands). He has extensive experience in ADME sciences with a particular focus on PK optimization, human PK prediction, biotransformation, bioanalysis and the use of in silico approaches in drug discovery.


 Speaker Profile

Ph.D., Chief Strategy Officer and Head of Drug Discovery, BioSymetrics

Biography
Stacie is a pharmaceutical R&D and biotech leader with expertise in AI and machine learning applications for drug discovery. At BioSymetrics she guides the company on its drug discovery and partnering strategies, with a focus on translating human-relevant disease biology. Prior to BioSymetrics, Stacie led collaborations and partnerships in the AI-powered drug discovery space as Vice President and Head of AI Molecular Screening Partnerships at Atomwise. Previously she established and co-led the Accelerating Therapeutics for Opportunities in Medicine (ATOM) consortium, a public-private partnership developing machine learning tools to accelerate drug discovery. She worked at GSK for more than 13 years, starting as a process chemist and moving up into R&D strategy and operations roles where she led several change initiatives and teams. Stacie holds a B.S. in Chemistry from University of California Berkeley and a Ph.D. in chemistry from University of California Irvine.


 Speaker Profile

Ph.D., Vice President, Janssen R&D Strategy and Operations, Johnson & Johnson

Biography
Dr. Tommaso Mansi is currently leading the AI/ML and Digital Health team at the Janssen R&D Data Science division. Dr. Mansi’s focus is on the development of AI solutions that enable deriving actionable insights from multimodal, multiscale data, to support and help accelerate drug discovery and development. Prior to joining Janssen, Dr. Mansi was at Siemens Healthineers, Digital Technology and Innovation. Dr. Mansi’s research interests cover artificial intelligence in healthcare, medical imaging, computational physiology, AI for biology, and image-guided therapy. Dr. Mansi received several awards for his work, gave multiple keynotes at international conferences and events. He holds 60+ granted US patents, co-edited 1 monograph and co-authored 100+ scientific publications.


 Speaker Profile

CEO, xCures Inc.

Biography
Mika has more than 20 years of commercial strategy and leadership experience in life sciences, with a focus on novel technologies. Over the last 10 years, Mika has concentrated on evidence-based medicine and tools to transform healthcare and clinical development. Before joining xCures Mika was the Chief Commercial Officer of Doctor Evidence, LLC. Prior to Doctor Evidence he was the General Manager of Clinical Development Services at diaDexus, SVP of Client and Market Development at Evidera, VP of Sales and Marketing at Archimedes, and held sales management and sales operations roles at Quintiles, Invitrogen and Tripos.


 Speaker Profile

Director, Business Development, Envisagenics

Biography
Kevin leads the business development efforts to form research collaboration partnerships with biopharma companies. Over the years, Kevin has worked in small-to-midsize biotechs and CROs gathering a wide spectrum of experience in pre- and post-IND development. With his previous role at Integrium, he has helped kickstart an investment arm leading equity and bridge financing investments with micro-cap and small-cap public biopharma companies.

Talk
AI-driven Drug Discovery Platform for Splicing Driven Diseases
Introduction to Envisagenics’ SpliceCore drug discovery platform and its application of RNA-splicing analytics to identify new therapeutic targets. The impact of transparent machine learning algorithms for downstream experimental validations. Case study – translating a novel splicing derived target identified by SpliceCore into the wet lab.


 Speaker Profile

M.D., Founding & Former Chief Innovation Officer, MedStar Health

Biography
Mark Smith is an emergency medicine physician who for the past 11 years has led a broad initiative to catalyze innovation in a large not-for-profit healthcare system, helping build centers in simulation training, human factors in healthcare, and telehealth innovation. He was co-creator of the Azyxxi/Amalga clinical information system which was in continuous use in hospitals for 22 years. Dr. Smith’s interests include digital health, advanced computational tools, complex systems theory, information visualization, disaster medicine, catalyzing sustainable and self-organizing change, and scaling that change within and across large systems of care. Prior to his appointment as director of the MedStar Institute for Innovation, Dr. Smith served as chair of the department of emergency medicine at MedStar Washington Hospital Center, Georgetown University School of Medicine, and at The George Washington University Hospital. He is a graduate of Swarthmore College (mathematics), Stanford University (computer science), and Yale University (medicine).


 Speaker Profile

M.D., DPHIL, CEO, Arctoris Ltd

Biography
Martin-Immanuel Bittner is the CEO of Arctoris, a biotech company combining wet lab automation and machine learning for accelerated small molecule drug discovery. Martin graduated as a medical doctor from the University of Freiburg in Germany, followed by his DPhil in Oncology as a Rhodes scholar at the University of Oxford, where he co-founded Arctoris. He has extensive research experience covering both clinical trials and preclinical drug discovery and is an active member of several leading cancer research organisations, including EACR, AACR, and ESTRO. Martin is a Fellow of the RSA and an elected member of the Young Academy of the German National Academy of Sciences and of Sigma Xi.


 Speaker Profile

M.D., Chief Medical Science Officer, Sema4

Biography
William K. Oh, M.D. is Chief Medical Science Officer at Sema4, a patient-centered health intelligence company focused on precision medicine. He is also an internationally recognized medical oncologist with over 25 years of clinical and translational research experience and leadership roles at major NCI-designated cancer centers. He continues to see cancer patients in his capacity as Clinical Professor of Medicine at Icahn School of Medicine at Mount Sinai. William has authored more than 330 articles, reviews, books and book chapters related to genitourinary cancers. He has conducted multiple clinical cancer trials and has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association.


AI & Data Science Showcase:
Sema4

Sema4 is a Patient-Centered Health Intelligence Company Leveraging AI, Genomics and Other Deep Data.

REPRESENT: Providing Access to Precision Oncology to All
Sema4 launched the REPRESENT study in community oncology practices caring for patients with advanced cancer in diverse, underserved populations. REPRESENT will perform comprehensive genomic profiling, hereditary cancer testing and clinical data including SDOH and correlate outcomes to these findings.

 Speaker Profile

Ph.D., VP, Global Head In Silico Discovery & External Innovation, Janssen

Biography
Jim Edwards is currently leading a multi-disciplinary group of computational & data scientists providing predictive and design tools across all modalities within the Therapeutics Discovery organization at Janssen, starting at project inception through the identification of clinical candidates. Primary to this, Jim was US Regional Head, Discovery Chemistry at Janssen Research & Development, leading drug discovery teams in South Francisco & La Jolla CA, Boston, MA, and Spring House, PA. These teams were responsible for the design and synthesis of small molecule drug candidates working with partners across DPDS and all six Therapeutic Areas within JRD. From 1999-2014, Jim led various Immunology medicinal chemistry groups at Janssen which delivered clinical-stage molecules against multiple novel first-in-class targets. Jim received his Ph.D. from the University of Illinois, Urbana-Champaign, working with Professor Scott Denmark, and performed post-doctoral studies with Professor Lanny Liebeskind at Emory University.


 Speaker Profile

Vice President, Genomics and Interoperability, Epic

Biography
Since coming to Epic more than 25 years ago with a background in physics and mathematics, Peter has designed, developed, and implemented a broad array of EHR-related technology at some of the world’s most well-known healthcare institutions, helping along the way to foster widespread interoperability between providers, patients, laboratories, and other partners. For the last several years, he has helped lead Epic’s precision medicine efforts, transforming genomics into computable data for clinical care and research.


 Speaker Profile

Ph.D., Co-Founder, Director of Biology, Fountain Therapeutic

Biography
Cell Biologist studying the intersection of metabolism, stem cell and regenerative biology, and aging.


 Speaker Profile

Ph.D., CEO, BioAge

Biography
Kristen Fortney is the co-founder and CEO of BioAge, a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging. By targeting these pathways with a large and mechanistically diverse portfolio of drugs, BioAge will unlock opportunities to treat or even prevent diseases of aging in entirely new ways. Kristen’s scientific background is in aging biology and bioinformatics. She received her PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford University where she was a fellow of the Ellison Medical Foundation / American Federation for Aging Research.


 Speaker Profile

Ph.D., Chief Scientific Officer, Engine Biosciences

Biography
Steve joined Engine Biosciences as Chief Scientific Officer in May 2018. Prior to joining Engine, Steve was Senior Vice President and CSO at Relypsa where he developed a pipeline of gut-restricted polymer therapeutics targeting systemic diseases. Before that he was Vice President, Research Biology at Nektar Therapeutics (NASDAQ: NKTR), a leader in polymer conjugate therapeutics, where for four years he managed global oncology and pain research efforts. Prior to Nektar, he was Senior Vice President, Research at KAI Pharmaceuticals. While at KAI, Steve led discovery efforts, including the company’s lead compound for the treatment of secondary hyperparathyroidism, which served as the basis for the company’s eventual acquisition by Amgen. Earlier in his career, Steve held senior research positions at Chiron Corporation and Thios Pharmaceuticals. He holds a Ph.D. in Molecular Biology, a M.A. and B.A. in Biochemistry, all from University of Cambridge, England.

Talk
Target and Biomarker Identification Using ML and CRISPR Screening
Engine Biosciences is uniquely applying proprietary machine-learning algorithms and ultra high-throughput CRISPR-based validation technology to identify clinically relevant targets and patient selection biomarkers in oncology. In our talk we would outline the differentiating features of the technology platform and showcase case studies of successful target and biomarker discovery leading to drug development programs.


 Speaker Profile

M.D., CSO, Ochre Bio

Biography
Quin is an MD/PhD with few extra degrees in genomics, mathematics, and statistical/machine learning. He uses deep genomic phenotyping technologies to develop RNA therapies for chronic liver disease. He started his first liver genomics company 17 years ago, and was most recently Head of Cellular and Systems Genomics for Novo Nordisk before co-founding Ochre Bio. Ochre Bio is a series A company, with labs in Oxford, Taipei, and New York where they regenerate human livers not good enough for transplantation. Think farms of livers on machines being refurbished by direct RNA reprogramming, so that fewer patients die waiting for a new liver.


 Speaker Profile

DPhil, CTO & President of Platform, Relation Therapeutics

Biography
Originally a specialist in systems biology, Lindsay joined GlaxoSmithKline in 2014 from the faculty of King’s College London. He started GSK’s first Data Science group, before becoming VP of AI/ML Engineering. He joined AstraZeneca as VP of AI in 2020, delivering complex models into production and publishing in some of machine learning’s most respected forums. He also led a small data science team working on the critical path of the Oxford-AstraZeneca COVID vaccine. His background spans machine learning, data science and bioinformatics but also human physiology, metabolic biochemistry and metabolomics. He has previously held academic appointments in both Australia and the UK. He holds a DPhil in Physiology from Oxford, has published more than 40 articles in peer-reviewed journals and is an accomplished public speaker. Before becoming a scientist, he was a successful musician and record producer and counts a number of UK Top Ten singles and multiple platinum albums to his credit.


 Speaker Profile

Executive Director, Applied AI and Data Science, City of Hope

Biography
Nasim leads the applied AI and data science department at City of Hope, one of the largest cancer research and treatment organizations in the United States. She helps supervise teams that are responsible for applying machine learning in clinical decision support and patient care, research, and precision medicine, as well as operations and finance. Before joining City of Hope in 2017, Nasim co-founded an AI company focusing on social media data mining and financial markets and political events prediction. She continues to advise startup companies on successful implementation of AI solutions. Nasim holds a master’s degree in computer science from Southern Illinois University and a bachelor’s degree in computer engineering from Khaje Nasir Toosi University in Tehran, Iran. On a personal level, Nasim enjoys an active lifestyle in sunny Los Angeles and has a passion for fitness and sports. She plays soccer and beach volleyball and goes to the gym every day!


 Speaker Profile

M.D., Ph.D., Professor of Medicine, Harvard Medical School and Co-Founder, Atman Health

Biography
Calum MacRae is a physician and scientist who works on disease mechanisms, translational genomic medicine and digital innovation. He is the PI of the AHA/Verily/AstraZeneca/Quest Diagnostics funded One Brave Idea program and the Apple Heart & Movement Study, as well as an Associate Member of the Broad Institute of Harvard and MIT and a Principal Faculty Member in the Harvard Stem Cell Institute. He was previously Chief of Cardiovascular Medicine at Brigham and Women's Hospital.

Talk
Systematizing Chronic Care
Data ingestion in medicine is typically a series of incompletely linked episodes. Systematizing all care transactions at an individual patient level offers the potential to create the data streams necessary to optimize chronic disease management, stratify individual risk in novel ways and reimagine clinical workflows.